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ABSTRACT
Objective: Till date, a very few prospective studies have examined the association between serum homocysteine levels and the risk of stroke and 
stroke subtypes in Indian populations.
Methods: A prospective, case - control study of Indian subjects 10–90 years of age was conducted using frozen serum samples from 103 participants 
in cardiovascular risk surveys collected from December 2017 to November 2018. By the end of 103, we identified 55 incidents of severe strokes, one 
control subject per case was selected by matching for sex, age, community, year of serum storage, and fasting status. Serum total homocysteine levels 
were measured by Cobas c-311.
Results: Compared with control subjects, total (n_206), hemorrhagic (n_106), and ischemic (n_87) strokes had higher geometric mean values of total 
homocysteine and higher proportions of homocysteine −25.0 μ mol/L. Homocysteine was estimated after adjustment for body mass index, smoking, 
alcohol intake, hypertension, and other cardiovascular risk factors. The excess risk of total and ischemic strokes did not vary significantly according 
to sex, age, smoking status, or hypertensive status.
Conclusion: High total homocysteine concentrations were associated with the increased risk of total stroke, more specifically ischemic stroke) 
Capsuloganglionic and frontoparietal infarct (8 each)., among Indian men and women.
Keywords: Homocysteine, Stroke, Hemorrhage, Atherosclerosis.
INTRODUCTION
High levels of homocysteine, in fasting or non-fasting state, have been 
reported to be more prevalent in patients with stroke as opposed to control 
subjects [1,2]. However, it can reflect an instead the cause, homocysteine 
concentrations can increase after the onset of acute stroke [3]. That’s 
why, to decrease the bias, we have collected the desirable data for this 
prospective study. However, our findings from prospective studies were 
found to be incompatible. Various prospective studies of numerous 
subjects depicted a significant relationship among homocysteine and 
the probability of total [4- 8] or ischemic strokes, 8 while no correlation 
was found by others. Blockage in the cerebral artery, plaque formation, 
and embolus are usually found in ischemic stroke [9,10]. There have 
not been many prospective studies about the role of homocysteine on 
the probability of stroke, especially in South Rajasthan. Although few 
studies have shown; hyperhomocysteinemia was more prognostic for 
risk of lacunar infarction than other stroke subtypes [8]. It is important 
to investigate the significance of homocysteine levels and the risk of total 
stroke and other subtypes of stroke among Indian men and women. We 
hypothesized a priori that the risk of ischemic stroke was increased by 
hyperhomocysteinemia, more specifically right front-parietal infarct, left 
cerebella infarct, but not the risk of hemorrhagic stroke among Indian 
men and women. To test this hypothesis, we conducted a prospective, 
casecontrol study including men and women belonging to the southern 
population of Rajasthan, India, using stored serum samples.
METHODS
Source of data
Patients seeking treatment in the department of neurology and/or 
Medicine in Geetanjali Medical College and Hospital, Udaipur. From 
December 2017 to November 2019.
This study was conducted on 102 consecutive patients of age 
>18 years with a history of acute ischaemic stroke. Data were 
collected with a thorough history and clinical examination 
with detailed neurological evaluation along with appropriate 
investigations.
Inclusion criteria
Patients with a history of acute ischemic stroke with age >18 years 
of age either male or female, patients who presented within 48 h 
since the onset of symptoms according to the American association 
of Neurology criteria and confirmed by neuroimaging (magnetic 
resonance imaging and computed tomography scan) were included in 
this study.
(Definition of ischemic stroke: An episode of neurological 
dysfunction caused by focal cerebral, spinal, or retinal infarction). 
A written informed consent was obtained from all the study 
participants.
Exclusion criteria
Patients with a history of diabetes mellitus, structural or valvular heart 
disease, cerebral infarction associated with trauma or tumor. Patients 
with transient ischemic attack, HIV-AIDS, Vitamin B12 deficiency, 
venous infarct, coagulation disorders and patients who did not given 
consent were excluded from this study.
Analysis of sample was run on Cobas e-311 by Enzymatic Photometry. 
It is a technique which is estimates the depth of thickness of a solution 
through which light passes. Statistical analysis of result was done by 
pad prism graph.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i10.42674. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
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RESULTS
One hundred and two ischemic stroke incidents were identified during 
follow-up. Table 1 shows the characteristics of risk of total stroke 
incidents and of particular stroke subtypes were compared with 
control subjects. The average age was 52 years for total stroke, varying 
from 53 years to 79 years for subtypes. The systolic and diastolic blood 
pressure in patients who suffered a stroke was found to be higher in 
comparison to control group subjects. Intake of alcohol was higher in 
cases in comparison to control subjects for all stroke patients.
In the age group of 61 years–70 years, maximum number of patients 
were found. 6, 9, and 20 cases, respectively, of mild, moderate, and 
severe morbidity were observed.
DISCUSSION
The key highlight of our study was that the elevated concentrations 
of fasting blood serum total homocysteine were strongly associated 
with the increased prevalence of ischemic stroke attacks, especially 
Capsuloganglionic and Frontoparietal infarct in patients belonging to 
the southern part of Rajasthan, India. Patients in the highest quartile of 
homocysteine were two times higher with respect to the probability of 
occurrence of stroke as opposed to persons having low Homocysteine 
levels in blood serum. These associations did not alter substantially 
after adjustments were made due to the known cardiovascular risk 
factors, such as smoking and hypertension. No significant association 
was found between homocysteine levels and risk of hemorrhagic 
stroke. However, implications of elevated homocysteine on risk of 
intraparenchymal and subarachnoid hemorrhages separately were 
found to be uncertain due to the limited number of subjects.
As per our knowledge, this is the first study with the aim of 
spotlighting a significant relation between total homocysteine levels 
and consequential risk of ischemic strokes among the population of 
Southern Rajasthan. The extent of the correlation among homocysteine 
and risk of stroke was found to be congruous with the previous studies.
Age or status of smoking did not show any significant impact on the 
risk of ischemic stroke. Numerous previous studies have pointed out a 
stronger relationship between homocysteine and atherosclerosis and 
that of occurrence of stroke against hypertensive and non-hypertensive 
subjects. The link between ischemic stroke, hyperhomocysteinemia with 
hypertension is well grounded. Due to the fact that hypertension is the 
dominant risk factor for stroke. Exact underlying mechanisms and effect 
of hyperhomocysteinemia on risk of ischemic stroke are not yet clear.
Hyperhomocysteinemia causes a rise in arterial blood pressure, thus 
increasing the risk of ischemic stroke. In the current study, a higher 
homocysteine level of 3-_mol/L was associated with 2.8–mm Hg higher 
systolic and 1.2 –mm Hg higher diastolic blood pressure levels taking 
in consideration the adjustment for age (year), sex, alcohol intake, 
and BMI with use of antihypertensive medication. We have concluded 
positive associations between serum homocysteine levels and risk of 
ischemic strokes, however, the relation of blood pressure with the same 
is yet to be made clear.
Elevated total homocysteine inflictsoxidative injury upon vascular 
endothelial cells and impairs the production of nitric oxide, a strong 
vascular relaxing factor, from the endothelium. Hyperhomocysteinemia 
also enhances adhesion of platelets to endothelial cells, promotes 
growth of vascularsmooth muscle cells, and is associated with higher 
levels of prothrombotic factors such as _-thromboglobulin, tissue 
plasminogen activator, and factor VIIc [11,12].
The strong association between homocysteine levels and risk of lacunar 
infarction observed in our study should be noted (Tables 3 and 4). This 
finding is concordant with previous findings from clinical studies that 
show homocysteine levels were higher in inpatients with subcortical 
vascular encephalopathy, a type of dementia with subcortical diffuse 
white-matter lesions or Hyperhomocysteinemia can be affected by 
food intake, and thereby, it can be referred to as a flexible risk factor 
of a stroke. Folic acid and B-vitamins, required for the remethylation 
of homocysteine and formation of methionine, are the essential dietary 
contributing factor, and plasma homocysteine levels had been shown to 
decrease by daily supplementation [13-15].
Several trials and clinical interventions have been conducted to assess 
the role of supplementation on cardiovascular risk and increase the 
survival ratio of patients as well as healthy subjects [13,15].
In our study serum homocysteine value was altered in 65 patients 
i.e. below 15 μmol/L. The mean homocysteine value was 19.21 which 
Table 1: Risk characteristics among cases and control subjects













Case 102 52±8.3 23.7 138 82 27 15 5.2 0.86
Control subjects 102 51±7.6 22.18 134 78 22 12 4.3 0.44
Left capsuloganglionic infarct 6 45±3.2 22.15 136 76 14 13 5.4 0.65
Left cerebellar infarct 7 53±5.6 23.14 132 78 13 17 3.7 0.32
Left frontal infarct 5 51±4.2 22.17 134 78 12 15 5.6 0.25
Left frontoparietal infarct 6 45±6.2 21.45 134 76 22 12 4.7 0.84
Left medullary infarct 3 62±8 22.45 132 76 12 13.7 3.8 0.45
Left occipito-temporal infarct 3 46±6.4 21.35 136 78 26 12 3.6 0.65
Left parietal infarct 5 51±4.3 22.04 132 76 25 14 4.5 0.65
Left parietooccipital infarct 4 46±3.9 21.04 134 74 22 18 5.0 0.54
Left pontine infarct 4 72±5.3 22.35 136 78 25 13 4.6 0.56
Left thalamic infarct 4 69±2.3 21.34 138 80 12 15 5.0 0.67
Occipital infarct 4 68±7.3 22.58 132 78 27 12 4.8 0.68
Right capsuloganglionic infarct 8 63±5.3 21.07 132 76 26 13.7 4.7 0.84
Right cerebellar infarct 5 54±4.3 23.06 134 78 22 14 4.7 0.68
Right frontal infarct 6 59±3.4 22.37 138 76 24 12 4.5 0.56
Right fronto-parietal infarct 8 61±5.2 21.45 134 80 22 11 5 0.74
Right medullary infarct 2 61.87±3.2 22.08 132 78 24 15 4.3 0.58
Right occipito-temporal infarct 2 62±2 21.08 136 80 28 13 3.7 0.67
Right parietal infarct 6 58±4 20.45 134 78 24 11 4.5 0.98
Right parietal occipital infarct 4 55±8 23.12 134 80 22 18 5 0.54
Right pontine infarct 5 52±4 22.14 132 78 28 13 4.1 0.68
Right thalamic infarct 6 48±6 21.34 136 76 27 16 3.8 0.56
BMI: Body mass index
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was higher as compared to the study of Kwon et al. who reported 11.4. 
There was no statistical difference found between the homocysteine 
level and severity of stroke, p = 0.142, and so Homocysteine value is not 
correlated (R = 0.169, p = 0.489) with NIHSS score and it does not vary 
with NIHSS score (Table 5).
Though in our study we have observed that there were no correlation 
in between serum homocysteine level and severity of stroke. While 
we have found higher level of serum homocysteine in patients of 
stroke with mild and moderate cases. We have found 21–30 μm/L 
serum homocysteine levels in 8, 14, 17 mild, moderate, and severe 
cases, respectively. Similarly, there were more than 30 μm/L serum 
homocysteine levels in 3,3 moderate and severe cases of stroke. 
Higher values of serum homocysteine were there but differences 
were not statically significant (p > 0.05) in severe cases of stroke 
(Tables 1,2,5).
The result concluded in our study was in accordance with the study 
conducted by Wang et al. who also reported that the homocysteine 
values are not a predictive factor of the outcome at 3 months and 1 year 
after acute cerebral infarction among elderly patients [16,17].
Table 2: Case control differences in serum total homocysteine levels (μmol/L)





Left capsuloganglionic infarct 22.42±1.32 0.0001S 3 <0.001
Control 13.12±1.23
Left cerebellar infarct 21.42±4.56 0.0023S 4 0.005
Control 12.32±2.31
Left frontal infarct 23.34±6.78 0.0365S 2 0.0001
Control 11.23±1.23
Left frontoparietal infarct 18 0.26±3.66 0.057S 3 0.05
Control 15.34±1.34
Left medullary infarct 16.45±3.96 0.0651 NS 2 0.051
Control 12.12±0.12
Left occipito-temporal infarct 11.32±2.56 0.0684NS 1 0.99
Control 10.23±2.12
Left parietal infarct 14.45±3.25 0.0847NS 4 0.05
Control 12.32±2.35
Left parietooccipital infarct 20.36±2.13 0.0641NS 3 0.002
Control 18.32±1.1
Left pontine infarct 16.12±2.15 0.0032S 2 0.021
Control 12.34±1.23
Left thalamic infarct 18.34±5.21 0.0052S 3 0.03
Control 7.34±1.35
Occipital infarct 12.15±15 0.0912NS 3 0.084
Control 11.32±2.11
Right capsuloganglionic infarct 17.23±1.6 0.078NS 7 0.065
Control 12.35±1.34
Right cerebellar infarct 18.34±3.47 0.063NS 4 0.05
Control 12.34±1.23
Right frontal infarct 13.4±8.34 0.097NS 5 0.06
Control 11.32±2.35
Right fronto-parietal infarct 37.23±4.23 0.0001S 3 0.0001
Control 8.52±5.38
Right medullary infarct 13.34±1.34 0.094NS 1 0.005
Control 11.22±3.21
Right occipito-temporal infarct 12.37±2.67 0.65NS 1 0.02
Control 10.23±1.23
Right parietal infarct 19.34±6.34 0.005 S 4 0.02
Control 13.56±2.65
Right parietal occipital infarct 11.26±7.32 0.63NS 3 0.003
Control 10.23±1.0
Right pontine infarct 12.15±4.34 0.63NS 3 0.05
Control 9.64±1.25
Right thalamic infarct 13.24±2.34 0.56NS 4 0.05
Control 10.15±1.23
Table 3: Age‑wise distribution and severity of stroke
Age group Moderate Moderate severe Severe
11–20 0 1 0
21–30 1 2 0
31–40 0 0 4
41–50 2 3 3
51–60 2 9 16
61–70 6 9 20
71–80 2 6 10
81–90 1 3 2
Table 4: Homocysteine level and severity of stroke
Homocysteine level Moderate Moderate severe Severe
4–15 5 12 21
16–20 1 4 14
21–30 8 14 17
More than 30 0 3 3
p=0.412, not significant. Homocysteine value is not correlated with NIHSS score 
and it does not varies with NIHSS score
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CONCLUSION
Serum homocysteine levels were not correlated with the severity of 
stroke in a younger age group. Serum homocysteine level did not depict 
any relation with age and sex in the early age group. It is predictive risk 
factors for the severity of stroke only after 55 years of age.
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